retatrutide clinical trials brazil 🚨Breaking: Retatrutide's first Phase 3 T2D data just dropped. ▸ A1C: −2.0% at 40 weeks ▸ Weight: −36.6 lbs (−16.8%) at 12 mg ▸ No weight loss plateau — curve still descending Effects of once-weekly subcutaneous retatrutide

Safety and efficacy of semaglutide added to Japanese patients with insulin-treated type 2 diabetes: A randomized, placebo-controlled, double-blind trial (SUSTAIN Japan)

Semaglutide can influence the kidneys, especially in people with existing kidney problems

Blood Sugar Control When Using Both Medications Together Steroids raise blood glucose by increasing insulin resistance and stimulating the liver to release stored glucose, while semaglutide lowers blood sugar by improving insulin secretion and cellular glucose uptake

And in June 2026, the first dedicated diabetes Phase 3 trial (TRANSCEND-T2D-1) confirmed 16.8% weight loss alongside -2.0% HbA1c reduction in 537 type 2 diabetes patients

Journal of Clinical Endocrinology and Metabolism